Mark B. Juckett, MD
Vice Chair, Clinical Affairs and Quality, Department of Medicine, University of Wisconsin, and Director, Bone Marrow
Transplant Program, University of
Wisconsin Carbone Cancer Center
Acute myeloid leukemia (AML) is diagnosed at a median age of 68 years, well beyond an age in which intensive therapy and allogeneic hematopoietic stem cell transplantation (HSCT) is typically considered an option. This approach is not easily applied to patients 60 years and older because of limitations caused by comorbidities, performance status, and frailty. In addition, older patients (here defined as those 60 years and older) tend to have disease that is more aggressive, harbors high-risk cytogenetics or molecular lesions (ie, p53
mutations), and is less sensitive to cytotoxic chemotherapy.
... to read the full story